骨质疏松症
医学
2型糖尿病
脆性骨折
骨矿物
健骨
重症监护医学
骨密度
骨密度保护剂
糖尿病
物理疗法
内科学
内分泌学
作者
Angela Sheu,Jerry R. Greenfield,Chris White,Jacqueline R. Center
标识
DOI:10.1016/j.tem.2022.02.006
摘要
There is substantial, and growing, evidence that type 2 diabetes (T2D) is associated with skeletal fragility, despite often preserved bone mineral density. As post-fracture outcomes, including mortality, are worse in people with T2D, bone management should be carefully considered in this highly vulnerable group. However, current fracture risk calculators inadequately predict fracture risk in T2D, and dedicated randomised controlled trials identifying optimal management in patients with T2D are lacking, raising questions about the ideal assessment and treatment of bone health in these people. We synthesise the current literature on evaluating bone measurements in T2D and summarise the evidence for safety and efficacy of both T2D and anti-osteoporosis medications in relation to bone health in these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI